21 CFR 803.33 User Facility Reporting

21 CFR Part 803 is the FDA's Medical Device Reporting regulation. It establishes when manufacturers, importers, and user facilities must report certain device-related adverse events and malfunctions. The rule covers reportability criteria, submission timelines, recordkeeping, and annual reporting obligations. Its purpose is to help FDA monitor device safety issues after products are in use and identify trends that may require corrective action.

21 CFR 803.33 addresses annual reporting by user facilities. User facilities must submit annual summaries of reportable events to FDA on the required schedule and maintain records supporting those submissions. This requirement works alongside immediate reporting obligations for deaths and serious injuries. Strong internal controls are essential so complaint files, event evaluations, and prior submissions are accurately captured and reflected in the annual report.

A user facility generally includes hospitals, ambulatory surgical facilities, nursing homes, outpatient diagnostic facilities, and treatment centers that use medical devices in patient care. Physician offices are typically excluded unless they meet specific criteria under the regulation. Because classification affects reporting obligations, organizations should confirm whether their facility type falls within FDA's MDR definition before building procedures or making reportability decisions.

User facilities must report device-related deaths to both FDA and the manufacturer, and serious injuries to the manufacturer or to FDA if the manufacturer is unknown. These reports are generally due within 10 work days after becoming aware of information that reasonably suggests a reportable event occurred. Timely intake, escalation, and documented decision-making are critical to meeting the deadline consistently.

Organizations should maintain complaint and incident records, event investigation files, reportability assessments, copies of submitted MDRs or annual reports, correspondence, and supporting evidence used to reach reporting decisions. Records should show dates of awareness, escalation steps, conclusions, and submission timing. A complete audit trail helps demonstrate that the facility evaluated events consistently and met both reporting and recordkeeping obligations under Part 803.

A reportability assessment should review the event facts, device involvement, patient outcome, available clinical information, and whether the incident meets the definitions of death, serious injury, or other reportable criteria under FDA MDR rules. The decision should be documented with a clear rationale, not just a conclusion. Standardized triage procedures, trained reviewers, and quality oversight reduce inconsistent judgments and missed reporting obligations.

Elexes offers a range of user facility reporting services, including reportability assessments, complaint governance support, internal audits, compliance training, regulatory outsourcing, and agency response preparation. These services cover the full compliance lifecycle — from event assessment and complaint intake to post-market governance — helping organizations build defensible reporting workflows and reduce missed deadlines.

Regulatory consultants can review procedures, assess complaint and incident workflows, evaluate reportability decisions, support annual reporting preparation, and identify documentation gaps before inspections or audits. They also help align complaint handling, post-market surveillance, CAPA, and risk management interfaces so reporting decisions are made consistently. This is especially valuable for organizations with limited internal RAQA bandwidth or complex post-market compliance responsibilities.